54 Antibody

What are the main types of 54 antibodies used in research and what epitopes do they recognize?

Several distinct "54 antibodies" are relevant for different research applications:

• Sigma 54 Monoclonal Antibody [33.7]: A mouse monoclonal antibody that recognizes bacterial/archaeal Sigma 54, an alternative sigma factor involved in bacterial gene transcription. This antibody has confirmed reactivity with Escherichia coli and Bordetella pertussis. It's also known as glnF, ntrA, RNA polymerase sigma 54 factor, and rpoN antibody .

• SPC-54: A rat monoclonal anti-mouse PC antibody that inhibits activated Protein C (APC) by blocking access to its active site, inhibiting enzymatic activity by >95% .

• Antibody 54 (RMT4-54): Recognizes mouse Tim-4 (T cell, Ig, mucin), which is expressed on antigen presenting cells but not on T lymphocytes .

• CD54 antibody (Clone 84H10): Targets the CD54 antigen (ICAM-1), a 90 kDa transmembrane glycoprotein that mediates adhesion of T lymphocytes with antigen-presenting cells .

• Anti-p54 monoclonal antibodies: Five monoclonal antibodies (2A7, 2D9, 4G5, 3F2, and 3D1) developed against the structural p54 protein of African Swine Fever Virus (ASFV) .

How do isotype differences among 54 antibodies affect experimental design and interpretation?

The isotype characteristics of 54 antibodies significantly impact experimental applications:

• Sigma 54 Antibody [33.7] is a mouse IgG1 kappa antibody produced using the Balb/c Sp2/0 cell line . This common isotype provides good stability and works well with most secondary detection systems.

• SPC-54 is a rat monoclonal antibody specifically selected for its ability to block murine APC activity in vivo, making it suitable for mouse models while minimizing host anti-antibody responses .

• TIM-4 Antibody (clone 54/RMT4-54) is available PE-conjugated for direct detection in flow cytometry applications without requiring secondary antibodies .

• Anti-p54 monoclonal antibodies share identical isotypes as shown in this data table:

These isotype characteristics affect secondary antibody selection, Fc receptor interactions, complement activation, and protein A/G binding properties in purification or immunoprecipitation experiments .

What molecular mechanisms explain how certain 54 antibodies block their target proteins' functions?

Different 54 antibodies employ distinct blocking mechanisms:

For SPC-54, detailed mechanistic studies demonstrate that this antibody inhibits APC activity by directly blocking access to the enzyme's active site. Evidence comes from active site titration experiments using biotinylated FPR-chloromethylketone, which showed that SPC-54 prevents this titrant from binding to APC's active site. This explains the >95% inhibition of APC's enzymatic activities observed in functional assays .

For CD54 antibody (clone 84H10), the blocking mechanism involves preventing the interaction between ICAM-1 and its integrin binding partner LFA-1, thereby disrupting cell-cell adhesion essential for immune cell interactions .

For antibodies targeting Tim-4 (clone 54), the blocking mechanism likely involves preventing Tim-4 interaction with Tim-1, which would disrupt T cell expansion and cytokine production. Since Tim-4 also serves as a phosphatidylserine receptor, these antibodies may interfere with the engulfment of apoptotic cells .

What are the optimal protocols for using 54 antibodies in Western blotting applications?

When optimizing Western blotting with 54 antibodies, several critical parameters require careful consideration:

Sample preparation varies by application. For detecting antigen-antibody complexes as demonstrated with SPC-54:PC complexes, non-denaturing PAGE without SDS should be used to preserve complex integrity. This approach was crucial in demonstrating the formation of antibody:antigen complexes in vivo .

For the anti-p54 monoclonal antibodies, Western blot screening successfully detected an approximate 65kDa fusion protein with all five antibody clones, demonstrating their utility for this application .

Additional optimization considerations include:

• Selection between colorimetric, chemiluminescent, or fluorescent detection based on required sensitivity

• Multiple exposure times to ensure detection within the linear range

• Optimization of membrane blocking conditions to minimize background while maintaining specific signal

• Inclusion of appropriate positive and negative controls, as demonstrated in the SPC-54 studies where controls included boiled antibodies or PBS vehicle

For analyzing antibody-antigen complexes in complex samples like plasma, consider supplementary techniques such as immunoprecipitation with protein G-agarose beads followed by Western blotting to provide direct evidence of complex formation .

How should flow cytometry experiments using 54 antibodies be designed for maximum sensitivity?

For optimal flow cytometry with 54 antibodies, follow these methodological guidelines:

Antibody titration is essential. For TIM-4 Monoclonal Antibody (54/RMT4-54), it's recommended to use ≤0.25 μg per test (100 μL final volume). The documentation emphasizes that "careful titration is essential for optimal performance" .

Cell numbers should be empirically determined but may range from 10^5 to 10^8 cells/test according to the TIM-4 antibody specifications .

Viability dye inclusion is specifically recommended for Tim-4 staining, with 7-AAD suggested as an appropriate choice. This highlights the importance of excluding dead cells that can bind antibodies non-specifically and generate false positive results .

For PE-conjugated antibodies like TIM-4 (54/RMT4-54), instrument settings should be optimized for:

• Excitation: 488-561 nm

• Emission: 578 nm

• Compatible lasers: Blue, Green, or Yellow-Green

Sample preparation should include proper filtration (0.2 μm post-manufacturing filtration is specified for the TIM-4 antibody) to remove aggregates that could affect flow cytometer performance and data quality .

For multicolor panel design, carefully consider spectral overlap and appropriate compensation controls, especially when incorporating 54 antibodies into complex immunophenotyping panels.

What methodological considerations are essential when using 54 antibodies in in vivo experiments?

The SPC-54 studies provide valuable insights for designing in vivo experiments with 54 antibodies:

Dosage determination is critical. For SPC-54, a single injection of 10 mg/kg was sufficient to neutralize circulating PC in mice for at least 7 days. This provides a starting point, though optimization may be necessary for different experimental questions .

The timing of administration can dramatically affect outcomes. In endotoxemia experiments with SPC-54, administration 7 hours after LPS challenge increased mortality from 50% to 100%, demonstrating the critical importance of timing relative to other experimental manipulations .

Duration of effect must be considered in experimental timelines. The SPC-54 studies demonstrated that a single dose maintained functional knockdown of the PC system for 7 days, with PC antigen levels returning to normal by day 14 .

Monitoring antibody-antigen complexes provides valuable information about ongoing target blockade. The SPC-54 research employed multiple techniques:

• Western blot analysis under denaturing conditions for total PC antigen levels

• Non-denaturing PAGE to visualize antibody:antigen complexes

• Immunoprecipitation with protein G-agarose to directly demonstrate complex formation

Control groups must be carefully designed. The SPC-54 studies used both boiled antibodies and PBS vehicle as controls to distinguish specific antibody effects from non-specific effects .

How can researchers distinguish between specific and non-specific binding when using 54 antibodies?

To establish binding specificity with 54 antibodies, researchers should implement multiple validation approaches:

Isotype controls are essential. All five anti-p54 monoclonal antibodies were IgG1 with kappa light chains, making an IgG1 kappa isotype control appropriate for establishing background binding levels .

Multiple antibody validation provides increased confidence. The approach taken with anti-p54 antibodies where five different monoclonal antibodies (2A7, 2D9, 4G5, 3F2, 3D1) against the same protein were developed and tested in parallel demonstrates how convergent results from multiple antibodies increase confidence in specificity .

Immunoprecipitation followed by Western blotting provides direct evidence of specific binding. The SPC-54 studies used protein G-agarose pull-down followed by Western blotting to confirm that the antibody was specifically binding to PC in plasma .

Testing under both native and denatured conditions provides complementary information. The anti-p54 antibodies were validated using both Western blot (denatured conditions) and immunofluorescence (native conditions), confirming their specificity across different protein conformations .

For Tim-4 Antibody (54/RMT4-54), the well-characterized expression pattern (present on antigen presenting cells but not on T lymphocytes) allows for internal positive and negative controls within mixed cell populations .

How should researchers interpret changes in antibody-antigen complex levels in time-course experiments?

Interpreting time-course data for antibody-antigen complexes requires careful consideration:

The SPC-54 research revealed an important phenomenon: PC antigen levels paradoxically increased at 24 and 48 hours after antibody injection despite functional PC being depleted. This was explained by the formation of SPC-54:PC complexes that had longer circulation times than free PC. This demonstrates why both functional and antigenic measurements are necessary for accurate interpretation .

Non-denaturing PAGE analysis of plasma samples from days 0, 1, 3, 7, and 14 after SPC-54 infusion revealed that antibody:antigen complexes persisted for at least 7 days before free PC began to reappear at day 14. This provides a timeline for interpreting functional effects in relation to complex formation .

The SPC-54 researchers employed multiple complementary techniques to validate their findings:

• Western blot analysis under denaturing conditions (for total antigen levels)

• Non-denaturing PAGE (to visualize antibody:antigen complexes)

• Immunoprecipitation with protein G-agarose (to directly demonstrate complex formation)

• Functional assays (to confirm the biological effect of the antibody)

When interpreting changes in complex levels, researchers should distinguish between antigen depletion versus functional blockade. The SPC-54 experiments demonstrated that while PC antigen was still present (and even elevated) in plasma, it was functionally neutralized by antibody binding .

What approaches can help resolve contradictory results when using 54 antibodies across different experimental platforms?

When facing contradictory results across platforms, consider these methodological approaches:

Validate across multiple assays, as demonstrated with the anti-p54 monoclonal antibodies, which were tested using indirect ELISA, Western blot, and immunofluorescence assays. This multi-platform validation can help identify platform-specific issues that might explain contradictory results .

Control experiments are essential. The SPC-54 research used multiple controls, including boiled antibodies and vehicle controls. Similarly, for TIM-4 antibody flow cytometry applications, a viability dye (7-AAD) was recommended to exclude non-specific binding to dead cells .

Optimize technical parameters for each platform. For Western blotting with Sigma 54 Antibody, the recommendation to determine optimal antibody dilution by titration underscores the importance of platform-specific optimization rather than relying on standard concentrations .

Consider epitope accessibility differences between platforms. The SPC-54 studies demonstrated that this antibody blocks the active site of APC—such mechanistic information can help explain why an antibody might work in some assays but not others depending on protein conformation .

When reconciling contradictory results, systematically evaluate each platform's strengths and limitations, the specific conditions under which each result was obtained, and whether differences in sample preparation might explain the discrepancies.

How can 54 antibodies be utilized in the development of competitive ELISA assays?

The development of competitive ELISA (cELISA) assays using 54 antibodies involves several methodological considerations:

Antibody selection criteria should be established. The researchers developing anti-p54 antibodies evaluated five monoclonal antibodies (2A7, 2D9, 4G5, 3F2, and 3D1) to determine which would perform best in a competitive ELISA format. This screening process is crucial because not all antibodies that work well in direct ELISA formats will necessarily perform optimally in competitive assays .

Validation requires well-characterized samples. The anti-p54 researchers used eight ASFV positive serum samples (from experimentally infected pigs) and four negative serum samples (from specific-pathogen free pigs). These samples were selected based on their OD values in indirect ELISA against p54 recombinant antigen, ensuring a range of antibody titers for testing the competitive format .

Optimization considerations include:

• Determining optimal coating concentration of recombinant antigen

• Titrating the monoclonal antibody concentration for maximum sensitivity and specificity

• Establishing appropriate blocking and washing conditions

• Determining optimal sample dilution ranges

• Setting appropriate cut-off values to distinguish positive from negative samples

The advantage of competitive ELISA for diagnostic applications is that it can be used with samples from any species without requiring species-specific secondary antibodies, making it versatile for veterinary or wildlife disease surveillance .

How can 54 antibodies contribute to understanding protein-protein interactions in cell signaling pathways?

54 antibodies can serve as powerful tools for dissecting protein interactions in signaling pathways:

Blocking functional interactions: The CD54 antibody (clone 84H10) inhibits ICAM-1 mediated adhesion to LFA-1, which is crucial for T cell interactions with antigen-presenting cells. By blocking this specific interaction, researchers can determine the contribution of ICAM-1/LFA-1 binding to downstream signaling events .

Studying co-stimulatory pathways: TIM-4 Antibody (54/RMT4-54) targets a protein that interacts with TIM-1 and leads to T cell expansion and cytokine production. This antibody can be used to investigate how TIM-4/TIM-1 interactions contribute to T cell activation and differentiation pathways .

Investigating phagocytosis signaling: Since TIM-4 has been shown to be a receptor for phosphatidylserine and may play a role in engulfment of apoptotic cells, the RMT4-54 antibody can be used to study the signaling pathways involved in this crucial immune process .

In vivo pathway manipulation: The SPC-54 studies demonstrated how antibody-mediated blockade of the Protein C pathway affected outcomes in both thromboembolism and endotoxemia models. This approach can be applied to study how various 54 antibody targets contribute to complex signaling networks in vivo .

By systematically blocking specific interactions with well-characterized antibodies, researchers can build a detailed understanding of the complex signaling networks that govern cellular interactions and responses.

What methodological approaches allow 54 antibodies to be used in studying in vivo disease models?

The SPC-54 studies provide an excellent methodological framework for using 54 antibodies in disease models:

In thromboembolism models, SPC-54 administration caused a major decrease in mean survival time compared to controls (7 min vs. 42.5 min, P = 0.0016) and decreased lung perfusion by 54% as measured by vascular perfusion methodologies using infrared fluorescence of Evans blue dye .

For endotoxemia models, SPC-54 infused 7 hours after endotoxin administration increased mortality from 42% to 100% (P < 0.001), demonstrating the critical role of the Protein C system in modulating endotoxin-induced pathology .

Methodological considerations for using antibodies in disease models include:

• Establishing the appropriate dosing regimen (10 mg/kg of SPC-54 was sufficient to neutralize circulating PC)

• Determining the optimal timing of antibody administration relative to disease induction

• Selecting appropriate endpoints (survival, tissue perfusion, etc.)

• Including proper controls (boiled antibody, vehicle controls)

• Monitoring antibody:antigen complex formation to confirm target engagement

• Using multiple complementary techniques to validate in vivo findings

These methodological approaches allow 54 antibodies to serve as powerful tools for understanding the contributions of specific molecular pathways to disease pathogenesis and for evaluating potential therapeutic interventions.